Clinical Trials Logo

Clinical Trial Summary

People affected by Severe Acute Respiratory Syndrome (SARS) by COVID-19 virus my require a long lasting invasive mechanical ventilation life support. To prevent damages to the lungs a number of protective lung ventilation measures are taken, one of them encounters the positive end expiratory pressure (PEEP) titration. Up to date, it is unclear the best method to titrate PEEP considering this unconventional syndrome compared to other etiologies. In addition to the long lasting advanced life support and bedridden condition, other factors may affect respiratory and peripheral muscle function of these patients. Therefore, the investigators intend to follow up these patients randomized to one of the three-arm experimental PEEP titration and after ICU discharge their status on clinical, laboratory and physical functions assessments.


Clinical Trial Description

Introduction: Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome - Coronavirus-2 (SARS-CoV-2) requires mechanical ventilatory (MV) life support. In this scenario, lung protective strategies have been recommended for avoiding ventilator induced lung injuries mainly by inappropriate positive end expiratory pressure (PEEP) titration. However, the best method of PEEP titration for these patients remains unclear, since its clinical and morphofunctional phenotype may differ from the conventional acute respiratory distress syndrome (ARDS) phenotype resulted from other etiologies. In addition, these patients' condition of long lasting MV dependency and bed restriction may lead to deterioration of respiratory and peripheral muscles functions. Objective: To compare the clinical and laboratory evolution and the respiratory and peripheral muscle functions in mechanically ventilated patients with COVID-19 submitted to PEEP titration by the following methods: ARDSNet protocol, driving pressure (DP) and electrical impedance tomography (EIT), as well as following them up after hospital discharge. Methods: This is a controlled, randomized, double blind clinical trial with 90 mechanically ventilated patients to be randomized in one of the 3 PEEP titration- related groups: ARDSNet protocol, Driving Pressure-DP (electing PEEP level by the lowest DP) and by the EIT (PEEP selected will be the closest level above the intercept point of cumulated collapse and overdistension percentage curves). Clinical, laboratory, oxygenation, ventilation, respiratory and regional mechanics data, as well as peripheral muscle outcomes (strength and functionality) will be monitored from intubation to extubation in the supine and prone position. The outcomes of respiratory and peripheral muscles functionality will be monitored for six months after hospital discharge. All ethical principles will be respected with either written Free and Consent Term by the patient or relatives at the intensive care phase or at the post ICU discharge phase. Data will be registered for posterior analysis, which considers the difference between groups with p <0.05. Expected results: Based on this study, it is expected to identify the Peep titration method associated to the greater beneficial and less deleterious effects in critically ill patients on MV. Also to address appropriate lung protective ventilation strategy for these patients and to detect respiratory and peripheral muscle disorders as early as possible in critically ill survivors. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05024500
Study type Interventional
Source University of Pernambuco
Contact
Status Completed
Phase N/A
Start date October 21, 2020
Completion date December 30, 2022

See also
  Status Clinical Trial Phase
Completed NCT03909854 - Pragmatic Investigation of Volume Targeted Ventilation-1 N/A
Recruiting NCT02637011 - Surviving ARDS: The Influence of Quality of Care and Individual Patient Characteristics on Quality of Life N/A
Completed NCT02288949 - Stratification of the Acute Respiratory Distress Syndrome
Recruiting NCT02574169 - Alveolar Recruitment Maneuvers, Intracerebral Hemodynamic and Oxygenation N/A
Completed NCT04548739 - Cerebral Autoregulation in Pediatric ECMO (ECMOX 2)
Terminated NCT04511650 - Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019 Phase 2
Recruiting NCT01339533 - Airway Pressure Release Ventilation (APRV) Versus AC/VC Conventional Ventilation Phase 2
Active, not recruiting NCT01274260 - Trial of Steroids in Pediatric Acute Lung Injury/ARDS Phase 2
Recruiting NCT03296059 - Transfusion of Red Blood Cells for Acute Respiratory Distress Syndrome(ARDS) in Neonates N/A
Terminated NCT04609865 - Impact of Intravenous Lidocaine on Clinical Outcomes of Patients With ARDS During COVID-19 Pandemia Phase 3
Active, not recruiting NCT04009330 - Clinical Evaluation of a Point of Care (POC) Assay to Identify Phenotypes in the Acute Respiratory Distress Syndrome
Not yet recruiting NCT06127381 - An Open-label Study of the Safety and Pharmacokinetics of the TGKP Phase 1
Not yet recruiting NCT05847517 - Metoprolol in Acute Respiratory Distress Syndrome (MAIDEN) Phase 3
Completed NCT01854424 - Validation of the Percentage of Alveolar Fibrocyte as Biomarker During ARDS N/A
Completed NCT03870009 - Validation of a Semi-automatized Method to Detect Cyclic Hyperinflation on CT-scan in ARDS N/A
Completed NCT04311697 - Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure Phase 2/Phase 3
Recruiting NCT02095444 - Using Human Menstrual Blood Cells to Treat Acute Lung Injury Caused by H7N9 Bird Flu Virus Infection Phase 1/Phase 2
Recruiting NCT04460859 - RecruitmEnt Assessed by eleCtRical Impedance Tomography
Completed NCT01926093 - Low Dose Lung CT Scan for Quantitative Analysis in ARDS Patients N/A
Terminated NCT01506401 - The Oscillation for Acute Respiratory Distress Syndrome (ARDS) Treated Early (OSCILLATE) Trial Phase 3